Abstract. To investigate the genotype-phenotype correlation in chinese familial and sporadic hypertrophic cardiomyopathy, specific exons of the myosin binding protein-c gene (MYBPC3) were screened in six families with hypertrophic cardiomyopathy (HCM; FHCM) and in 20 patients with sporadic HCM (SHCM) from the anhui Province region of china. The V896M mutation was detected for the first time in China in two families with FHCM. The mutation was not found in 100 healthy control subjects. No mutations of MYBPC3 were detected in any of the SHCM patients. In contrast to previous reports, the V896M mutation may be a disease-causing mutation in China, and exon 27 of MYBPC3 may be a mutational hotspot in FHCM patients. However, mutations of MYBPC3 were not prevalent among SHCM patients.
Introduction
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease, and is characterized by a very heterogeneous morphologic expression and clinical course (1, 2) . With an estimated prevalence in the general population of approximately 1:500, there are potentially over one million patients with HCM in China alone (3) . Genetic screening is a necessary tool for a definite diagnosis of HCM, particularly in subjects with atypical or borderline phenotypic expression (4) . Several sarcomeric and non-sarcomeric protein genes have been associated with the disease, and novel culprit genes are being described every year. Thus, comprehensive molecular screening for HCM represents a technical and economic challenge and is hardly feasible in China. The two most common sarcomeric genes involved in HCM are α-myosin heavy chain (MYH7) and cardiac myosin binding protein-c (MYBPC3). These genes account for a proportion of diseaseassociated mutations that was consistently high in Europe (5), despite wide fluctuations attributable to the different genetic backgrounds of the study subjects. Based on the screening of MYH7 in six families one year ago, we determined that the comprehensive screening of MYBPC3 may provide a favorable yield of genotyped index cases. The present study was undertaken in the same six unrelated Chinese families with HCM (FHCM) and in 20 patients with sporadic HCM (SHCM) at the Department of Cardiology of The First Affiliated Hospital of anhui Medical university.
Materials and methods

Clinical materials.
A total of 20 patients in six unrelated families (8 males and 12 females; age range 17-70 years) and 20 SHCM patients were identified through the patient register of the department of cardiology of our hospital and evaluated. The main clinicopathologic findings of these patients are summarized in Table I . The diagnosis of HCM was based on the presence of a maximal left ventricular wall thickness of at least 13 mm, determined by two-dimensional echocardiography. The absence of other causes of ventricular hypertrophy, such as hypertension, aortic stenosis, physical exercise or the use of some drugs, was confirmed in each patient. electrocardiographic and echocardiographic examinations were also performed in the six families. All individuals gave their informed consent for participation. The study was approved by the Ethical Committee of the hospital. To confirm the absence of any new putative mutation in the MYBPC3 gene among the healthy individuals, a total of 100 controls were genotyped. The controls did not have a history of cardiovascular disease, including HCM.
Genetic studies. MYBPC3 sequencing of genomic dna was prepared from peripheral blood leukocytes using a salting-out procedure. Exons 13, 15-16, 26 and 27 of the MYBPC3 gene, as well as the corresponding exon-intron boundaries (gi:89161188) (Table II) , were sequenced in all probands of the six families and 20 SHCM patients. PCR reactions were performed in a GeneAmp PCR system (Hema-240; PCR Zhuhai Biotechnology Group, P.R. China). Each reaction included 1,000 ng of genomic dna, 7.5 pmol of each primer, 500 µmol of dNTP, 2.5 µl 10X buffer and 2.0 units Taq dna Mutation of V896M in cardiac myosin binding protein-c gene in two Chinese families with hypertrophic cardiomyopathy polymerase (Sangon Biotechnology, P.R. China). The PCR conditions for the cardiac MYBPC3 gene were denaturing at 94˚C for 4 min, followed by 32 cycles of denaturing at 94˚C for 40 sec, annealing at 59.5-62˚C for 40 sec and extension at 72˚C for 90 sec, with a final extension at 72˚C for 10 min. Genomic DNA was PCR-amplified with the primer pairs and annealing temperatures summarized in Table II . Each PCR product was analyzed on an ABI PRISM 3730Xl automated sequencer (Perkin-Elmer Applied Biosystems, uSA) according to dideoxy chain termination reaction sequencing reactions.
Results
Identification of the V896M-MYBPC3 missense mutation.
A 16750 G→G/A mutation at exon 27 of the MYBPC3 gene was detected in two probands (families D and E) among the six families, resulting in the replacement of a valine by methionine residue at amino acid 896 (gi:148596956) ( Fig. 1) . None of the 100 control subjects had the mutation. We then screened exon 27 of the MYBPC3 gene in other members of the same two families. The results showed that the mutation co-segregated with the disease (Fig. 2 , Table III ). Mutations of MYBPC3 were not detected in any of the SHCM patients. Table I . Main characteristics of the five patients with HCM in the two families showing the V896M mutation. The dimension of the left atrium was 56 mm while that of the left ventricular diastolic was 52 mm. The EF of 68%.
in family e, the V896M mutation of the MYBPC3 gene was detected in four cases. Three members were diagnosed with HCM. The proband (EⅡ:1), a 46-year-old woman, was diagnosed with HCM due to exertional chest stress 4 years prior. The father of proband was a 69-year-old man with a New york Heart Association functional class (NyHA FC) of Ⅳ who presented with frequent symptoms of chest stress. Echocardiography showed an interventricular septum thickness of 19 mm and posterior wall thickness of 11 mm. The dimension of the left atrium was 58 mm, while that of the left ventricular diastolic was 65 mm. The EF was 45%. The sister of the proband (EⅡ:3) was 43 years of age, and was diagnosed with HCM one year prior during a health examination. Finally, EⅢ:3 was a 15-year-old boy determined to carry the V896M mutation, and was confirmed to be healthy through electrocardiographic and echocardiographic examination. none of the patients were found to have left ventricular outflow obstruction, as determined by echocardiography, and none of all patients succumbed suddenly to the diease among the two families.
Discussion
HCM is generally considered to be a strictly autosomal dominant inherited disease, and manifests as left ventricular or interventricular septal asymmetrical hypertrophy. It exhibits variability in its phenotypes, wth clinical manifestations including dizziness, dyspnoea, syncope, angina, serious heart failure, and even sudden death (1). However, symptoms may also be absent, non-specific or late in onset. HCM is largely due to mutations in the genes encoding proteins of the sarcomere. Therefore, it is also called 'sarcomere disease' (6) .
The sarcomere complex is composed of thick and thin filaments, and plays a role in the contraction, construction and regulation of human myocardium filaments. MyBPC is a sarcomeric protein associated with the thick filament of striated muscle. It is located in the cross-bridge-containing A-band of the sarcomere in a structurally regular pattern of seven to nine (7). The core structure of MyBPC comprises seven class I immunoglobulin domains and three fibronectin type III (FnIII) domains, numbered from the N-terminus as domains 1-10 (C1-C10) in skeletal muscle. MyBPC has been assigned roles in both the structural assembly and stability of the sarcomere, as well as in the modulation of contraction.
The V896M mutation is located on the field of C7, while domains C7-C10 belong to the C-terminal part of the protein and have a high affinity for the light meromyosin (lMM) portion of myosin and for titin, the structural 'ruler' of the sarcomere. The C-terminal domain, C10, binds to four molecules of lMM via positively-charged amino acids present on its surface (8) . However, even though this domain is essential, it is not sufficient for maximal binding to myosin. The three adjacent domains (C7-C9) maximise the affinity of this binding and ensure correct incorporation into the A-band (9) .
The V896M mutation was first reported in two South African subpopulations by Moolman-Smook et al (10) . A subsequent study by Richard et al (11) showed that the presence of a heterozygous MYBPC3 variant (V896M) contributed to the phenotype severity, and was associated with early hypertrophy when present together with a heterozygous a355T MYH7 mutation. The authors suggested that the V896M variant acts as a modifier polymorphism on the expression of the phenotype.
While a previous study identified the V896M variant in 5/111 control individuals in (12), it was not found among the healthy controls in our study, and the mutation and the disease showed co-separation. It may therefore be a disease-causing mutation in china.
in the two families with the V896M mutation discussed here, the V896M variant of MYBPC3 was detected in six cases. Five of six family members were diagnosed as having HCM. only one was confirmed to be a healthy carrier through electrocardiographic and echocardiographic examinations. However, this one (EⅢ:3) is a 15-year-old boy, and studies have shown that patients with MYBPC3 mutations usually have a delayed age of onset (13) . long-term follow-up is therefore essential in this patient.
The penetrance in our study was calculated to be 83% (5/6 carriers). There were no obstructions in the left ventricular outflow tract in any of the patients, as determined by echocardiographic examination, and none of the patients in the two pedigrees succumbed suddenly to the disease. The carriers who were over 38 years of age had a normal left ventricular dimension and EF, but presented ventricular wall hypertrophy. Most of the 60-year-old carriers presented heart failure and a gradual decrease in the EF. Taken together, the results suggest that the phenotype becomes more malignant with increasing age. Thus, in the present study the V896M mutation was found to exhibit similar features to those reported by Richard et al (13) , including the delayed onset of clinical symptoms, slow development and a benign phenotype.
We previously reported three mutations (Family A, Arg663His of exon 18; Family B, Arg 723Gly of exon 20; Family C, Ile736Thr of exon 20; and Ile736Thr of exon 20 in 1 of 20 SHCM patients) of the MYH7 gene in the same six families and among 20 SHCM patients (Table III) (14) . Here, we report a mutation in the MYBPC3 gene in two of the same six families with HCM. In five of the six families, mutations in the MYBPC3 and MYH7 genes were detected. However, only 1 SHCM patient was found to have a Ile736Thr mutation of exon 20 in the MYH7 gene. This indicates that mutations of the MYBPC3 and MYH7 genes frequently occur among FHCM patients, but not among SHCM patients, in China.
in conclusion, we showed a missense mutation, V896M, in two Chinese families with a benign phenotype of HCM with mild clinical symptoms. MYBPC3 as well as MYH7 may be the dominant disease-causing genes in Chinese familial HCM patients, while the mutation rate of the MYBPC3 and MYH7 genes is significantly lower among sporadic HCM patients. Exon 27 of the MYBPC3 gene may be a mutational hotspot among Chinese FHCM patients.
